The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH/ISH 2016 | Pros and cons of combination therapy for multiple myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD from Oxford University Hospitals NHS Foundation Trust, Oxford, UK discusses the pros and cons of drug combinations for multiple myeloma (MM). According to Dr Ramasamy, clinical trials indicate that certain drug combinations work better for certain myeloma patients. The pros of combination therapy include that combination therapies can be tailored in various ways; for example, knowledge about a patient’s disease biology and frailty can be taken into consideration. The cons include the cost of the combination therapies. Further, Dr Ramasamy, discusses the future possibility of combining many different agents for treatment and bringing together different industry partners to do future studies; currently the cost of all the agents individually prohibits bringing them together. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.
